{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:40Z","timestamp":1787019640875,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,23]],"date-time":"2014-02-23T00:00:00Z","timestamp":1393113600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-244x-14-53","type":"journal-article","created":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T21:01:36Z","timestamp":1393102896000},"source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia"],"prefix":"10.1186","volume":"14","author":[{"given":"George","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,23]]},"reference":[{"issue":"3","key":"1562_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/11594470-000000000-00000","volume":"30","author":"AG Awad","year":"2012","unstructured":"Awad AG, Voruganti LNP: Measuring quality of life in patients with schizophrenia \u2013 an update. Pharmacoeconomics. 2012, 30 (3): 183-195. 10.2165\/11594470-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1562_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00023210-199912010-00005","volume":"12","author":"TL Patterson","year":"1999","unstructured":"Patterson TL, Kaplan RM, Jeste D: Measuring the effect of treatment on quality of life in patients with schizophrenia: focus on utility based measures. CNS Drugs. 1999, 12 (1): 49-64. 10.2165\/00023210-199912010-00005.","journal-title":"CNS Drugs"},{"issue":"13","key":"1562_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2165\/00023210-200418130-00004","volume":"18","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti LNP: The impact of atypical antipsychotics in quality of life on patients with schizophrenia. CNS Drugs. 2004, 18 (13): 877-893. 10.2165\/00023210-200418130-00004.","journal-title":"CNS Drugs"},{"issue":"5","key":"1562_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1023\/A:1008958925848","volume":"8","author":"DA Revicki","year":"1999","unstructured":"Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM: Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res. 1999, 8 (5): 417-426. 10.1023\/A:1008958925848.","journal-title":"Qual Life Res"},{"key":"1562_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-7525-1-31","volume":"1","author":"L Gee","year":"2003","unstructured":"Gee L, Pearce E, Jackson M: Quality of life in schizophrenia: a grounded theory approach. Health and Quality of Life Factors. 2003, 1: 31-40. 10.1186\/1477-7525-1-31.","journal-title":"Health and Quality of Life Factors"},{"key":"1562_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0959-4388(00)00068-4","volume":"10","author":"G Kuperberg","year":"2000","unstructured":"Kuperberg G, Heckers S: Schizophrenia and cognitive function. Curr Opin Neurobiol. 2000, 10: 205-2010. 10.1016\/S0959-4388(00)00068-4.","journal-title":"Curr Opin Neurobiol"},{"key":"1562_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.schres.2010.08.007","volume":"126","author":"S Shamsi","year":"2011","unstructured":"Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, Lindenmayer J-P, Malhotra AK: Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011, 126: 257-264. 10.1016\/j.schres.2010.08.007.","journal-title":"Schizophr Res"},{"key":"1562_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/oxfordjournals.schbul.a033363","volume":"25","author":"MF Green","year":"1999","unstructured":"Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia?. Schizophr Bull. 1999, 25: 173-182. 10.1093\/oxfordjournals.schbul.a033363.","journal-title":"Schizophr Bull"},{"key":"1562_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1477-7525-6-105","volume":"6","author":"A Briggs","year":"2008","unstructured":"Briggs A, Wild D, Less M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treated-related adverse events on quality of life: direct utility utilization. Health Qual Life Outcomes. 2008, 6: 105-10.1186\/1477-7525-6-105.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1562_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF02849966","volume":"24","author":"E Kim","year":"2007","unstructured":"Kim E, Levy R, Pikalov A: Personalized treatment with atypical antipsychotic medications. Adv Ther. 2007, 24 (4): 721-740. 10.1007\/BF02849966.","journal-title":"Adv Ther"},{"issue":"7","key":"1562_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2165\/00023210-200216070-00003","volume":"16","author":"JS Hellewell","year":"2002","unstructured":"Hellewell JS: Patients\u2019 subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 2002, 16 (7): 457-471. 10.2165\/00023210-200216070-00003.","journal-title":"CNS Drugs"},{"issue":"2","key":"1562_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00004850-199605002-00009","volume":"11","author":"AG Awad","year":"1996","unstructured":"Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP: Assessment of the patient\u2019s subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol. 1996, 11 (2): 55-59.","journal-title":"Int Clin Psychopharmacol"},{"key":"1562_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, David CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-244X-10-75","volume":"10","author":"AW Nyhuis","year":"2010","unstructured":"Nyhuis AW, Faries DE, Ascher-Svanum HA, Stauffer VL, Kinon BJ: Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010, 10: 75-10.1186\/1471-244X-10-75.","journal-title":"BMC Psychiatry"},{"key":"1562_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.psychres.2007.10.011","volume":"165","author":"B Puschner","year":"2009","unstructured":"Puschner B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, Tansella M, Becker T: Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res. 2009, 165: 224-33. 10.1016\/j.psychres.2007.10.011.","journal-title":"Psychiatry Res"},{"key":"1562_CR16","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.euroneuro.2008.04.003","volume":"3","author":"P Falkai","year":"2008","unstructured":"Falkai P: Limitations of current therapies: why do patients switch therapies?. Eur Neuropsychopharmacol. 2008, 3: S135-9.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1562_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence inpatients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002, 63: 892-909. 10.4088\/JCP.v63n1007.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1562_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.4088\/JCP.v65n1012","volume":"65","author":"O Freudenreich","year":"2004","unstructured":"Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC: Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004, 65 (10): 1372-6. 10.4088\/JCP.v65n1012.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1562_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.psychres.2006.12.010","volume":"158","author":"G Santone","year":"2008","unstructured":"Santone G, Rucci P, Muratori ML, Monaci A, Ciarafoni C, Borsetti G: Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Psychiatry Res. 2008, 158 (3): 324-34. 10.1016\/j.psychres.2006.12.010.","journal-title":"Psychiatry Res"},{"issue":"16","key":"1562_CR20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jpsychires.2009.05.003","volume":"43","author":"R Schennach-Wolff","year":"2009","unstructured":"Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller HJ, Riedel M: Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res. 2009, 43 (16): 1294-301. 10.1016\/j.jpsychires.2009.05.003.","journal-title":"J Psychiatr Res"},{"key":"1562_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.genhosppsych.2011.09.001","volume":"34","author":"AO Adelufosi","year":"2012","unstructured":"Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry. 2012, 34: 72-9. 10.1016\/j.genhosppsych.2011.09.001.","journal-title":"Gen Hosp Psychiatry"},{"key":"1562_CR22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/070674370404900504","volume":"49","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti LN: New antipsychotics, compliance, quality of life, and subjective tolerability \u2013 are patients better off?. Can J Psychiatry. 2004, 49: 297-","journal-title":"Can J Psychiatry"},{"key":"1562_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-244X-8-32","volume":"8","author":"G Morken","year":"2008","unstructured":"Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008, 8: 32-8. 10.1186\/1471-244X-8-32.","journal-title":"BMC Psychiatry"},{"key":"1562_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3810\/pgm.2011.03.2273","volume":"123","author":"L Citrome","year":"2011","unstructured":"Citrome L: Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgraduate Medicine. 2011, 123: 153-162. 10.3810\/pgm.2011.03.2273.","journal-title":"Postgraduate Medicine"},{"issue":"2","key":"1562_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4088\/JCP.12m07992","volume":"74","author":"JP McEvoy","year":"2013","unstructured":"McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A: Effectiveness of lurasidone in schizophrenia or schizoaffective disorder patients switched from other antipsychotics: a randomized, six-week, open-label study. J Clin Psychiatry. 2013, 74 (2): 170-9. 10.4088\/JCP.12m07992.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1562_CR26","first-page":"5","volume":"68","author":"PF Buckley","year":"2007","unstructured":"Buckley PF: Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry. 2007, 68 (6): 5-9.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1562_CR27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome L, Nasrallah HA: On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012, 13 (11): 1599-1613. 10.1517\/14656566.2011.626767.","journal-title":"Expert Opin Pharmacother"},{"key":"1562_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0920-9964(01)00161-X","volume":"56","author":"L Voruganti","year":"2002","unstructured":"Voruganti L, Awad G: Personal evaluation of transitions in treatment (PETIT) a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophren Res. 2002, 56: 37-46. 10.1016\/S0920-9964(01)00161-X.","journal-title":"Schizophren Res"},{"issue":"3","key":"1562_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"JE Ware","year":"1996","unstructured":"Ware JE, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care. 1996, 34 (3): 220-233. 10.1097\/00005650-199603000-00003.","journal-title":"Medical Care"},{"key":"1562_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-244X-10-2","volume":"10","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010, 10: 2-7. 10.1186\/1471-244X-10-2.","journal-title":"BMC Psychiatry"},{"key":"1562_CR31","first-page":"185","volume-title":"Antipsychotics and Mood Stabilizers: Stahl\u2019s Essential Psychopharmacology","author":"SM Stahl","year":"2008","unstructured":"Stahl SM: From antipsychotic agents. Antipsychotics and Mood Stabilizers: Stahl\u2019s Essential Psychopharmacology. 2008, New York: Cambridge University Press, 185-186. 3","edition":"3"},{"issue":"1","key":"1562_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/erp.10.2","volume":"10","author":"AG Awad","year":"2010","unstructured":"Awad AG: Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoeconomics Outcomes Res. 2010, 10 (1): 1-4. 10.1586\/erp.10.2.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"2\u20133","key":"1562_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0920-9964(99)00154-1","volume":"43","author":"L Voruganti","year":"2000","unstructured":"Voruganti L, Cortese L, Oyewumi L, Cernovsky A, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability side-effect profile and impact on quality of life. Schizophr Res. 2000, 43 (2\u20133): 135-145.","journal-title":"Schizophr Res"},{"issue":"6","key":"1562_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jval.2011.04.006","volume":"14","author":"D Papaioannou","year":"2011","unstructured":"Papaioannou D, Brazier J, Parry G: How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2011, 14 (6): 907-20. 10.1016\/j.jval.2011.04.006.","journal-title":"Value Health"},{"issue":"1","key":"1562_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1185\/030079908X253384","volume":"24","author":"S Ganesan","year":"2008","unstructured":"Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meuliend D: Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2008, 24 (1): 21-32.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1562_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","volume":"32","author":"S-W Kim","year":"2009","unstructured":"Kim S-W, Shin I-S, Kim J-M, Lee J-H, Lee Y-H, Yang S-J, Yoon J-S: Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009, 32 (5): 243-249. 10.1097\/WNF.0b013e31819a68b5.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"1562_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4088\/JCP.v64n0514","volume":"64","author":"PJ Weiden","year":"2003","unstructured":"Weiden PJ, Simpson GM, Potkin SG, O\u2019Sullivan RL: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003, 64 (5): 580-588. 10.4088\/JCP.v64n0514.","journal-title":"J Clin Psychiatry"},{"key":"1562_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hup.1057","volume":"24","author":"S-W Kim","year":"2009","unstructured":"Kim S-W, Shin I-S, Kim J-M, Lee S-H, Lee Y-H, Yang S-J, Yoon J-S: Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive functioning in patients with schizophrenia. Hum Psychopharmacol Clin Exp. 2009, 24: 565-573. 10.1002\/hup.1057.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1562_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-244X-9-54","volume":"9","author":"DE Faries","year":"2009","unstructured":"Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psych. 2009, 9: 54-","journal-title":"BMC Psych"},{"issue":"4","key":"1562_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG, Aripiprazole study group: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol (Berl). 2003, 166 (4): 391-9. 10.1007\/s00213-002-1344-3.","journal-title":"Psychopharmacol (Berl)"},{"issue":"1","key":"1562_CR41","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1503\/jpn.110096","volume":"37","author":"J Su","year":"2012","unstructured":"Su J, Barr AM, Procyshyn RM: Adverse events associated with switching from conventional antipsychotic drugs or risperidone to olanzapine. J Psychiatry Neurosci. 2012, 37 (1): E1-E2. 10.1503\/jpn.110096.","journal-title":"J Psychiatry Neurosci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-14-53\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-53","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T04:25:45Z","timestamp":1498105545000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-14-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-14-53","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,23]]},"article-number":"53"}}